ARS Pharmaceuticals, Inc. (SPRY) News
Follow ARS Pharmaceuticals, Inc. (SPRY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
ARS Pharmaceuticals 3Q 2026: Revenue $37.71M, EPS ($0.36) — 10-Q Summary
ARS Pharmaceuticals’ revenue increased from the prior-year quarter, primarily on higher global neffy unit sales. Net loss narrowed as operating expenses fell, mainly due to lower marketing-related expenses, partly offset
EARNINGS | Nov 05, 2026, 09:14 PM UTC
M
ARS Pharmaceuticals to Report Third-Quarter 2026 Results
ARS Pharmaceuticals says it will report its third-quarter 2026 financial results.
EQUITY | Oct 28, 2026, 08:03 PM UTC
L
SPRY - LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
SPRY - LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
REGULATION | Sep 15, 2026, 01:27 PM UTC
L
ARS Pharmaceuticals CEO to participate in upcoming investor conferences
ARS Pharmaceuticals said Donn Casale, President and CEO, will participate in upcoming investor conferences, according to a company announcement.
EQUITY | Sep 01, 2026, 08:08 PM UTC
L
SPRY - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SPRY - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 08:01 PM UTC
L
ARS Pharmaceuticals outlines priorities and reports Q2 2026 results
ARS Pharmaceuticals outlines strategic priorities, including a focused commercial strategy, and reports its second quarter 2026 financial results.
EARNINGS | Aug 13, 2026, 08:02 PM UTC
L
SPRY - ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Secon
SPRY - ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 11:30 AM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC
M
ARS Pharma Reaffirms 2027 Breakeven Goal
ARS Pharmaceuticals reaffirms its expectation to achieve cash-flow breakeven in 2027 despite missing July Neffy coverage wins
EARNINGS | Jun 25, 2026, 05:34 PM UTC
M
12 Health Care Stocks Move
Multiple health care stocks are moving in Thursday's intraday session, with gainers including Atlantic International and SELLAS Life Sciences, and losers including Nano X Imaging and Passage Bio
EQUITY | Jun 25, 2026, 05:05 PM UTC
H
SPRY -24% on Update
SPRY falls 24% premarket after providing commercial and financial updates, while other big cap stocks also decline on various news
EQUITY | Jun 25, 2026, 12:17 PM UTC
M
FUL, TCOM, HTZ Drop
H.B. Fuller, Trip.com, and Hertz Global are among the stocks moving lower in Thursday's pre-market session
EQUITY | Jun 25, 2026, 12:08 PM UTC
M
SPRY Lowers Guidance
ARS Pharmaceuticals lowers FY26 cash operating expense guidance, shares trade lower
EARNINGS | Jun 24, 2026, 08:48 PM UTC
M
ARS Pharma Lowers 2026 Expense Guidance
ARS Pharma lowers 2026 cash operating expense guidance to $248M and reaffirms path to cash-flow breakeven in 2027
EARNINGS | Jun 24, 2026, 08:44 PM UTC